Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Entasis Therapeutics Inc (ETTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11019
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. Entasis’ ETX0914, is an oral antibiotic for the treatment of uncomplicated gonorrhoea. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc (ETTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Partnerships 16
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Licensing Agreements 17
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Equity Offering 18
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc – Key Competitors 21
Entasis Therapeutics Inc – Key Employees 22
Entasis Therapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 14, 2018: Entasis Therapeutics reports third quarter 2018 financial results 24
Corporate Communications 26
May 01, 2018: Entasis Therapeutics Appoints David C. Hastings to Board of Directors 26
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 27
Product News 28
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 28
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 29
06/06/2018: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2018 30
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 31
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 32
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 33
Clinical Trials 34
Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis 34
Jun 06, 2018: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2018 35
May 14, 2018: Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282 37
Oct 12, 2017: Entasis Therapeutics Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program 38
Oct 09, 2017: Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials 39
Sep 28, 2017: Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017 40
Jun 07, 2017: Entasis Therapeutics Presents Data on Third Drug Candidate, ETX0282, an Orally Available, Extended-Spectrum eta-lactamase Inhibitor, at ASM Microbe 2017 41
Apr 21, 2017: Entasis Therapeutics to Present Data on ETX2514SUL at 27th European Congress of Clinical Microbiology and Infectious Diseases 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 12
Entasis Therapeutics Raises USD50 Million in Series B Financing 14
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 15
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 16
Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 17
Entasis Therapeutics Prices IPO of Shares for USD75 Million 18
Entasis Therapeutics Spin Out from AstraZeneca 20
Entasis Therapeutics Inc, Key Competitors 21
Entasis Therapeutics Inc, Key Employees 22

List of Figures
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kissei Pharmaceutical Co Ltd (4547):製薬・医療:M&Aディール及び事業提携情報
    Summary Kissei Pharmaceutical Co Ltd (Kissei) discovers, manufactures and sells a range of innovative pharmaceutical products and develops. The company's pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drug for obstetri …
  • Publix Super Markets, Inc.:企業の戦略・SWOT・財務分析
    Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Publix Super Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Council of Europe Development Bank:企業の戦略・SWOT・財務情報
    The Council of Europe Development Bank - Strategy, SWOT and Corporate Finance Report Summary The Council of Europe Development Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • TxCell SA (TXCL):企業の財務・戦略的SWOT分析
    Summary Txcell SA (Txcell) a subsidiary of Sangamo Therapeutics Inc, is a biotechnology company that develops personalized cellular immunotherapies using regulatory T cells (Treg) for the treatment of autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders. The …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • Warrnambool Cheese and Butter Factory Company Holdings Limited:企業の戦略・SWOT・財務情報
    Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cov …
  • Net One Systems Co Ltd (7518):企業の財務・戦略的SWOT分析
    Net One Systems Co Ltd (7518) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Chevron Corp (CVX):電力:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • Intelsat S.A. (I):企業の財務・戦略的SWOT分析
    Intelsat S.A. (I) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Greatship (India) Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Greatship (India) Ltd (GIL), a subsidiary of The Great Eastern Shipping Co. Ltd is an offshore oilfield service provider that offers shipping and transportation services. The company transports crude oil, petroleum products, gas and bulk commodities. It provides offshore logistics and drilli …
  • Senju Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Senju Pharmaceutical Co Ltd (Senju) researches, develops, manufactures and markets pharmaceutical products for eye, ear, nose, throat, and skin. The company offers a wide range of ophthalmological products. Its product portfolio includes prescription products, OTC medicines and veterinary dr …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066):医療機器:M&Aディール及び事業提携情報
    Summary Shandong Weigao Group Medical Polymer Company Ltd (Weigao) researches, develops, manufactures and sells disposable medical consumables, orthopedic materials and blood purification products. Its products include infusion sets, needles, blood bags, heart eluting stents, blood sampling products …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務分析
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sherman & Howard LLC:企業の戦略的SWOT分析
    Sherman & Howard LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mayo Clinic-製薬・医療分野:企業M&A・提携分析
    Summary Mayo Clinic (Mayo) is a not-for-profit medical practice and medical research organization. It provides comprehensive medical facilities and programs related to patient care services, research and medical education. It offers specialized medical care with medical departments and centers in mo …
  • Software AG:企業の戦略・SWOT・財務分析
    Software AG - Strategy, SWOT and Corporate Finance Report Summary Software AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Pharmaxis Ltd (PXS)-製薬・医療分野:企業M&A・提携分析
    Summary Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lu …
  • Mahindra Holidays & Resorts India Limited:企業の戦略・SWOT・財務分析
    Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Electricity Generating Authority of Thailand:企業の発電所・SWOT分析2018
    Electricity Generating Authority of Thailand - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Melrose Industries PLC (MRO):企業の財務・戦略的SWOT分析
    Summary Melrose Industries PLC (Melrose), formerly Wheelmark Plc is an investment company that offers buy, improve and sell manufacturing businesses. The company offers products such as air management, security, home automation and ergonomic and electricity generating equipments. Its business portfo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆